| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99283 |
Emergency department visit for the evaluation and management, moderate severity |
1,701 |
1,564 |
$304K |
| 99284 |
Emergency department visit for the evaluation and management, high severity |
1,058 |
888 |
$218K |
| 99285 |
Emergency department visit for the evaluation and management, high severity with immediate threat to life |
43 |
38 |
$13K |
| 80053 |
Comprehensive metabolic panel |
827 |
732 |
$10K |
| 85025 |
Blood count; complete (CBC), automated, and automated differential WBC count |
1,086 |
962 |
$9K |
| 80307 |
Drug test(s), presumptive, any number of drug classes; immunoassay |
116 |
107 |
$7K |
| 96375 |
Therapeutic injection; each additional sequential IV push |
82 |
75 |
$7K |
| J3490 |
Unclassified drugs |
1,868 |
1,414 |
$5K |
| 96374 |
Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance |
86 |
82 |
$4K |
| G0480 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed |
99 |
67 |
$3K |
| 87633 |
Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets |
12 |
12 |
$3K |
| 99282 |
Emergency department visit for the evaluation and management, low to moderate severity |
28 |
28 |
$2K |
| 97530 |
Therapeutic activities, direct patient contact, each 15 minutes |
39 |
12 |
$2K |
| 87801 |
Infectious agent detection by nucleic acid; amplified probe, multiple organisms |
49 |
41 |
$2K |
| 71045 |
Radiologic examination, chest; single view |
42 |
39 |
$2K |
| 36415 |
Collection of venous blood by venipuncture |
689 |
592 |
$2K |
| J7030 |
Infusion, normal saline solution , 1000 cc |
138 |
119 |
$2K |
| 96361 |
Intravenous infusion, hydration; each additional hour |
64 |
60 |
$2K |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
29 |
27 |
$1K |
| 93005 |
Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report |
49 |
47 |
$1K |
| 87798 |
Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism |
39 |
38 |
$1K |
| 81001 |
|
431 |
403 |
$995.40 |
| 84443 |
Thyroid stimulating hormone (TSH) |
32 |
26 |
$875.16 |
| 86780 |
|
64 |
56 |
$828.59 |
| 87651 |
Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe |
27 |
26 |
$758.03 |
| 86703 |
|
65 |
57 |
$732.50 |
| 85027 |
|
99 |
83 |
$597.18 |
| 87081 |
|
75 |
74 |
$495.42 |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
53 |
29 |
$468.53 |
| 87581 |
|
12 |
12 |
$347.34 |
| 87486 |
|
12 |
12 |
$347.34 |
| 87086 |
Culture, bacterial; quantitative colony count, urine |
33 |
25 |
$241.20 |
| 83735 |
|
34 |
33 |
$108.99 |
| 83690 |
|
13 |
13 |
$77.22 |
| 84484 |
|
14 |
14 |
$73.56 |
| 83605 |
|
12 |
12 |
$66.55 |
| A9270 |
Non-covered item or service |
28 |
27 |
$49.09 |
| 93010 |
Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only |
13 |
12 |
$42.27 |
| 85610 |
|
17 |
17 |
$39.20 |
| J2405 |
Injection, ondansetron hydrochloride, per 1 mg |
14 |
13 |
$30.42 |